Groundbreaking EV - 302 Trial Significantly Extends Overall Survival and Progression - Free Survival in Patients Treated with PADCEV ( enfortumab vedotin - ejfv ) and KEYTRUDA ( pembrolizumab ) in First - Line Advanced Bladder Cancer